As of the close on Friday, $S&P/ASX 200(XJO.AU)$ closed at 8,408.90 on Friday, up 1.19% in the past 5 days.
1. $HUB24 LTD(HUB.AU)$ +17.59%
The Hub24 share price is up 17.59% to $77.07. Investors have been buying this investment platform provider's shares following the release of another strong quarterly update.
Hub24 revealed that its platform funds under administration (FUA) increased 8% over the quarter to $98.9 billion. This represents a 36% increase on the prior corresponding period. Management advised that this was driven by record quarterly net inflows of $5.5 billion (up 23% on the prior corresponding period) and positive market movements of $1.8 billion.
HUB24 Limited has announced the issuance of 216,518 performance rights under its employee incentive scheme, which are not intended to be quoted on the AU. This strategic move is part of the company’s efforts to align employee rewards with long-term company performance, potentially enhancing employee motivation and contributing to the company’s growth and competitive positioning in the financial services industry.
2. $NETWEALTH GROUP LTD(NWL.AU)$ +14.45%
The Netwealth Group Ltd share price is climbing on Wednesday after posting its financials for three months ending December 2024.
The Netwealth share price had a good quarter on the chart and in the business with its fund flows. This marks the second consecutive quarter of record-breaking inflows for the company in FUA and FUM. FUA net inflows for the first half of FY25 were $8.5 billion alone, driven by "consistently high transition rates from existing financial intermediaries" and "strong conversion rates" from its pipeline.
The company also reported $517 million in institutional FUA net inflows. According to the latest Plan for Life industry analysis, Netwealth had the second-highest fund flows for any platform in the 12 months ending September 30, 2024.
3. $MEGAPORT LTD(MP1.AU)$ +13.83%
Data Storage Corporation announced that its subsidiary, CloudFirst Europe, has expanded its partnership with Megaport into the UK, marking a significant milestone in its global expansion strategy.
Building upon a successful relationship in North America, this expansion enables CloudFirst to leverage Megaport's Network as a Service platform, "Direct Connect", which simplifies access to top-tier cloud providers and hyperscalers such as AWS through secure, high-performance connectivity.
As part of the partnership, CloudFirst Europe will deploy infrastructure within Megaport's ecosystem of data centers and leverage its global private connectivity solutions to strengthen CloudFirst's IBMi Power Hosting and Infrastructure as a Service offerings.
4. $DEEP YELLOW LTD(DYL.AU)$ +12.36%
Deep Yellow Limited has announced the quotation of 70,848 ordinary fully paid securities on the AU, effective January 10, 2025. This move is a result of securities being issued, transferred, or reclassified due to the exercise of options or conversion of convertible securities, potentially enhancing the company’s liquidity and visibility in the market.
Deep Yellow views its flagship Tumas project as one of the most advanced greenfield uranium projects globally. While Deep Yellow continues to evaluate the project for an investment decision in March, its team will continue to work on the project engineering on site and conduct further drilling to boost the deposit’s reserves. The company will also look to secure its supply of water and power from Namibia’s utilities, as well as project financing.
By the end of December, it had A$238 million in cash and no debt.
5. $NEUREN PHARMACEUTICALS LTD(NEU.AU)$ +11.59%
Neuren Pharmaceuticals' stock is up by a considerable 13% over the past week.
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.
Neuren Pharmaceuticals has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 13% which is quite remarkable. Under the circumstances, Neuren Pharmaceuticals' considerable five year net income growth of 81% was to be expected.
Comments